

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS V LLC;
HAYMAN CREDES MASTER FUND, L.P.;
HAYMAN ORANGE FUND SPC – PORTFOLIO A;
HAYMAN CAPITAL MASTER FUND, L.P.;
HAYMAN CAPITAL MANAGEMENT, L.P.;
HAYMAN OFFSHORE MANAGEMENT, INC.;
HAYMAN INVESTMENTS, LLC;
NXN PARTNERS, LLC;
IP NAVIGATION GROUP, LLC;
J KYLE BASS; and ERICH SPANGENBERG,
Petitioner,

v.

BIOGEN MA INC.,
Patent Owner.

Case IPR2015-01993
Patent 8,399,514 B2

DECLARATION OF TAMMY SARNELLI

TABLE OF CONTENTS

I.	Introduction and Personal Background	1
A.	Education and Work Experience.....	2
B.	Involvement With Tecfidera® Development and Biogen’s BG-12 Team	5
II.	Biogen Carried Out an Extensive, Well-organized Regulatory Plan for Its BG-12 Product to Treat MS.....	10
A.	Planning and Conducting Nonclinical Safety Studies in Animals	12
1.	P00012-04-06 (6-Month Rat BG-12 Toxicity Study)	12
2.	P00012-04-11 (Two-Year Rat BG-12 Carcinogenicity Study)	14
3.	P00012-05-03 (Two-Year Mouse Carcinogenicity Study).....	15
4.	P00012-05-05 (11-Month Dog Toxicity Study).....	17
5.	P00012-05-08 (1-Year Monkey Toxicity Study)	18
B.	C-1900 (Phase 2 BG-12 Dose-Ranging Study in MS Patient-Volunteers)	20
C.	Summary of Nonclinical and Clinical Study Activities from September 2004 – March 2006	21
D.	Biogen’s Meetings and Communications with the FDA to Discuss the Filing of INDs for the Use of BG-12 to Treat Human Disease.....	22
1.	IND 69,852 (for psoriasis)	23
2.	IND 73,061 (for MS)	25

E. Biogen’s EOP2 Meeting to Discuss Phase 3 BG-12 Clinical Trials.....29

F. Follow Up with the FDA Following the EOP2 Meeting and Planning for Phase 3.....33

III. Conclusion37

I, Tammy Sarnelli, have personal knowledge of the facts stated herein and provide the following testimony:

I. Introduction and Personal Background

1. I am currently the Senior Director, Regulatory Affairs, at Biogen Idec, Inc. (“Biogen”), and have held that position since 2014. As Senior Director, Regulatory Affairs, I serve as the regulatory lead on new drug development programs (small molecule and biologic), and in this capacity provide oversight of independent review markets and global emerging markets for Tecfidera[®], Biogen’s newly-marketed multiple sclerosis product. I also serve as the regulatory representative on Biogen’s Clinical Trial Review Board, which evaluates clinical trial protocols across all therapeutic areas. My daily activities at Biogen include providing regulatory input and strategic guidance for new products, coordinating interactions with regulatory authorities on new product development, working to enhance the capabilities of Biogen’s Regulatory Affairs department, and supervising regulatory personnel (Associate Directors, Managers, and Senior Associates) within the department. I have been a Biogen employee for more than twenty-five years, the past fifteen of those as a member of Biogen’s Regulatory Affairs department.

2. I understand that the U.S. Patent and Trademark Office has initiated a proceeding involving Biogen’s U.S. Patent No. 8,399,514 (the “514 patent”).

3. I provide this declaration to document my work on the project that led to the regulatory approval of Tecfidera[®], a multiple sclerosis (“MS”) treatment involving the daily, oral administration of 480 mg of dimethyl fumarate (“DMF”).¹ I also document work done by others at Biogen, and also those contracted to do work on Biogen’s behalf, in developing Tecfidera[®], from at least May 2006 up to and including February 2007.

A. Education and Work Experience

4. Attached hereto as **Appendix A** true and correct copy of my current resume is being filed herewith as **Appendix A**. *See Appendix A* (resume of Tammy Sarnelli, hereinafter the “Sarnelli Resume”).

5. I am a graduate of Saint Anselm College, where I earned a Bachelor of Arts degree in biology in 1988. I later attended Suffolk University, where I was awarded a Master’s Degree in Public Administration/Health Care in 1995. *See Sarnelli Resume* at 1.

6. From 1988 to 1989 I worked as a Research Technician at the Dana Farber Cancer Institute, where I was responsible for managing laboratory testing

¹ I previously provided a declaration in Biogen’s Interference No. 106,023, which also involves the ’514 patent.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.